Monday, January 15, 2007

Novo Nordisk cut "small molecule" jobs

Novo Nordisk, the world's largest insulin maker, will cut as many as 180 jobs as the company stops research into non-biotechnology treatments.

Research and development will focus on exclusively on protein-based drugs, Bagsvaerd, Denmark-based Novo Nordisk said today in a statement to the Copenhagen stock exchange. Current projects in so-called "small molecules" will be disposed, the company said.

Bloomberg

No comments: